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Abstract: 
 
A major problem in the discovery of new biologically active compounds from natural products is 
the reisolation of known compounds. Such reisolations waste time and resources, distracting 
chemists from more promising leads. To address this problem, dereplication strategies are 
needed that enable crude extracts to be screened for the presence of known compounds before 
isolation efforts are initiated. In a project to identify anticancer drug leads from filamentous 
fungi, a significant dereplication challenge arises, as the taxonomy of the source materials is 
rarely known, and, thus, the literature cannot be probed to identify likely known compounds. An 
ultraperformance liquid chromatography–photodiode array–high-resolution tandem mass 
spectrometric (UPLC-PDA-HRMS-MS/MS) method was developed for dereplication of fungal 
secondary metabolites in crude culture extracts. A database was constructed by recording HRMS 
and MS/MS spectra of fungal metabolites, utilizing both positive- and negative-ionization 
modes. Additional details, such as UV-absorption maxima and retention times, were also 
recorded. Small-scale cultures that showed cytotoxic activities were dereplicated before 
engaging in the scale-up or purification processes. Using these methods, approximately 50% of 
the cytotoxic extracts could be eliminated from further study after the confident identification of 
known compounds. The specific attributes of this dereplication methodology include a focus on 
bioactive secondary metabolites from fungi, the use of a 10 min chromatographic method, and 
the inclusion of both HRMS and MS/MS data. 
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Article: 
 
Many natural product drug discovery programs utilize bioactivity-directed fractionation 
methodologies for the isolation of lead compounds from crude extracts, in which the bioassay 
results guide the purification processes.(1, 2) While countless studies demonstrate the utility of 
this approach in identifying new drug leads, with taxol and camptothecin possibly the most well-
known examples,(3-5) it is often criticized for resulting in the reisolation and recharacterization 
of previously known compounds. This criticism of natural products research grows in 
significance annually, as over 246 000 compounds have been described from Nature, with 
approximately 4000 new ones added each year.(6) Thus, to expedite the discovery of new leads 
and to avoid the reisolation of previously known compounds, it is crucial to discriminate 
between known versus new compounds as early as possible. This process, which is termed 
“dereplication”,(7) enables the efficient use of human and financial resources,(8, 9) so that 
efforts can be focused on the discovery of structurally novel compounds.(8, 10) 
 
Early dereplication strategies focused largely on botanical extracts. The ability to characterize a 
plant’s taxonomy (at least to the genus level) based on morphology can simplify the 
dereplication process, as it enables botanical extracts to be screened for known chemical 
compounds specific to the taxa under investigation. Some examples include colchicinoids 
in Colchicum spp.,(11) acetogenins in plants of the Annonaceae,(12) phenolics in the 
genus Lippia,(13) steroidal alkaloids in Buxus spp.,(14) and triterpenoids in the 
genus Actaea.(15) 
 
In contrast, dereplication can be more complicated for organisms of unknown taxonomy.(16, 17) 
This is the case for our ongoing research aimed at identifying anticancer drug leads from 
nonsporulating filamentous fungi.(18, 19) Fungi are known to produce structurally diverse 
secondary metabolites that display a wide range of biological activities. Although fungi are 
relatively underinvestigated,(20, 21) a major challenge with these organisms as a source of 
bioactive lead compounds is the production of mycotoxins, which can be observed across 
different fungal species. Examples of these include aflatoxins, ochratoxins, trichothecenes, 
citreoviridin, fumonisins, and various indole-derived tremorgenics.(22) Indeed, a promising side 
application for the presently described dereplication procedure is the rapid identification of 
mycotoxins in foods, as mycotoxins continue to present safety challenges for the food 
supply.(23, 24) While molecular methods have accelerated the process,(25) assignment of fungal 
taxonomy can be a tedious procedure, and regardless, only about 100 000 of the estimated 1.5 to 
5.1 million species of fungi have been ascribed a scientific name.(20, 21) Hence, the taxonomy 
of fungi being studied in natural products programs is often not known at all or only determined 
after compounds have been isolated. Thus, there is a critical need for better strategies to 
dereplicate crude fungal extracts for the presence of known chemical entities, including 
mycotoxins and other biologically relevant compounds. In doing so, resources for drug discovery 
can be devoted to those samples most likely to yield new chemical entities.(19) 
 
Several dereplication methods have been reported in the literature for fungal secondary 
metabolites; however, all of these are hampered by at least one, if not several, limitations, 
including long run times (30 min or more), low-resolution mass measurements, and/or lack of 
confirmatory MS-MS data.(16, 26-29) A recent LC-UV/vis-MS-based dereplication strategy 
utilized UV spectra (acquired with a photodiode array detector) and ESI+/ESI– time-of-flight MS 
for assignment of 719 microbial natural product and mycotoxin reference standards.(27) While 
effective, only 17% (29 compounds) of our database of cytotoxic fungal compounds overlapped 
with the standards used, as this earlier procedure did not have a focus on compounds with 
biological activity.(27) Moreover, a 30 min chromatographic method was utilized,(27) which 
may be too long for routine processing of scores of samples simultaneously, particularly for 
shared instruments. Finally, CID MS/MS data were not reported,(27) which serve to fingerprint 
and confirm the identity of dereplicated compounds. Thus, the goal of the present study was to 
harness the powerful resolution and short analysis time afforded by ultraperformance liquid 
chromatography (UPLC) coupled to the outstanding mass accuracy of an Orbitrap mass 
spectrometer to develop a rapid and effective method to dereplicate biologically active fungal 
extracts. In addition, MS/MS and UV (photodiode array) spectra were employed as an integral 
part of the strategy, so as to differentiate isobaric compounds often present in natural product 
extracts. Finally, given the likelihood of the coelution of compounds in complex mixtures 
separated over short (<10 min) chromatographic run times, a data analysis strategy was 
incorporated (ACD/IntelliXtract), aimed at rapidly deconvoluting complex LC/MS 
chromatograms. 
 
Results and Discussion 
 
The foundation of the present UPLC-PDA-HRMS-MS/MS dereplication procedure was the 
construction of a database for the identification of more than 170 fungal secondary metabolites 
via recording chromatographic retention times, UV data, and full-scan (high-resolution) mass 
spectra and MS/MS spectra in both positive and negative electrospray ionization (ESI) modes. 
The chromatographic and tune methods were developed using a mixture of 36 compounds 
representing diverse structural classes that ranged from terpenenoids to polyketides to 
depsipeptides. To test the developed method, a mixture of 10 structurally diverse compounds 
was prepared and analyzed (Figures S1 and S2, Supporting Information). The resulting 10 min 
chromatographic method and associated high-resolution mass spectra could be used to 
discriminate between all the compounds in the database. Of these, only two resorcylic acid 
lactones, 7-epi-zeaenol and 15-O-desmethyl-5Z-7-oxozeaenol,(30) did not ionize in the 
ESI+ mode, whereas 17 compounds, mostly trichothecenes,(31) did not ionize in the ESI– mode 
(Table S1, Supporting Information). Also, the molecular ion peaks of aphidicolin and 
viridicatumtoxin were the only ones not detected in the positive-ion mode, due to the facile loss 
of H2O; however, the molecular ion peak for the latter was observed in the negative-ion mode. 
All MS/MS fragmentation data were collected using collisionally induced dissociation (CID) 
with 30% collision energy, and the 10 most intense fragments for each compound were utilized 
in the database (Table S1, Supporting Information). 
 
To initiate the dereplication process, small-scale cultures of fungi were grown on a solid medium 
and extracted using previously described protocols;(30, 32-34) the extracts were then evaluated 
for cytotoxicity against a panel of human cancer cell lines in culture, including MCF-7, H-460, 
and SF-268 cells.(35, 36) Samples deemed active were prepared for analysis by dissolving a 
submilligram aliquot of the bioactive crude extracts in equal volumes of MeOH and dioxane to 
obtain a final concentration of 2 mg/mL. The subsequent dereplication strategy utilized a three-
step approach (Figure 1). First, UPLC-HRMS was used to acquire the TIC (total ion 
chromatogram) of the extract and hence measure the accurate masses of all ions detectable. This 
TIC was then uploaded into ACD MS Manager with add-in software Intellixtract, which cross-
referenced the molecular ion peaks with the database that was constructed as a list of compound 
names, corresponding molecular weights, and retention times (Table S1, Supporting 
Information). These results were then confirmed manually using HRMS data, and the MS/MS 
and UV spectra were compared with the database to verify the identity of any hits. The use of the 
MS/MS data, retention times, and UV spectra confirmed the identity of the compounds in the 
extract; the only exception would be for the possible, albeit rare, case of isomers. Moreover, the 
ACD/IntelliXtract software, which has the capability to extract all chromatographic components 
in the LC/MS data sets, expedited the identification process, due to its capability of resolving 
overlapping and coeluting components. Finally, using IntelliXtract, it was possible to reconstruct 
pure component chromatograms for each chromatographic component and annotate spectral 
peaks with the mass of the protonated or deprotonated molecule.(37) 
 
 
Figure 1. Schematic of the workflow for the proposed dereplication protocol. Aliquots of active 
fungal extracts were evaluated using a UPLC-PDA-HRESIMS-MS/MS method, the data were 
analyzed using ACD Laboratories Intellixtract software and compared with an in-house database, 
and extracts producing known compounds were excluded. 
 
Using these procedures, 106 small-scale culture extracts were dereplicated. All of these 
displayed sufficiently potent cytotoxicity against a small cancer cell line panel to warrant further 
investigation. However, on the basis of the dereplication results, 55 samples were ruled out as 
containing known compounds. By doing so, resources were prioritized on samples most likely to 
yield new compounds. The three examples shown below demonstrate the work flow of the 
dereplication methodology, illustrating its utility for a broad range of structural classes of 
bioactive natural products. 
 
 
 
Dereplication of Verticillins (Epipolythiodioxopiperazine Alkaloids) 
 
An extract of the filamentous fungus MSX 39480 displayed potent cytotoxic activity for the 
H460 cell line (94% and 88% inhibition of cell growth when tested at 20 and 2 μg/mL, 
respectively) and thus was subjected to the dereplication protocol. Seven 
epipolythiodioxopiperazine (ETP) alkaloids were dereplicated by matching retention times, 
HRMS, and MS/MS data, namely, 11′-deoxyverticillin (1), Sch 52900 (2), verticillin A (3), 
gliocladicillin A (4), gliocladicillin C (5), Sch 52901 (6), and verticillin H (7). To illustrate the 
value of the protocol, a compound eluting at 5.51 min with a m/z of 741.1285 was detected in the 
extract. The isotopic pattern of the molecular ion peak, in conjunction with intensity-ratio 
calculations, suggested the presence of four sulfur atoms. ACD/Intellixtract analysis of the 
UPLC-HRMS data identified this as compound 5, a dimeric ETP alkaloid, and the accurate mass 
and retention time data matched that of a standard of 5 (Figures 2 and 3). As a confirmation, 
excellent agreement between the MS/MS spectra of the standard and unknown was achieved 
(Figure 2). The same methodology was used to verify the identity of compounds 1–4, 6, 
and 7 (Figure 3). Dimeric ETP alkaloids are bioactive secondary metabolites reported to have 
potent cytotoxic(38-47) and antibacterial activities,(48-53) along with 
antiparasitic,(54) nematicidal,(55) antiviral,(56) and immunosuppressive properties.(57) Hence, 
this class of compounds has been well studied, including previously in our laboratory,(33) and, 
thus, their rapid dereplication allowed us to focus on other leads with a greater potential to yield 
new substances. 
 
 
Figure 2. (A) (+)-ESI SIC of crude MSX 39480 extract (m/z: 681, 695, 697, 711, 725, 727, 741). 
(B) Overlay of chromatographic peaks of gliocladicillin C. (C) (+)-HRESIMS of gliocladicillin 
C. (D) MS/MS CID fragmentation spectra of gliocladicillin C. 
 
Dereplication of Enniatins 
 
On the small scale, an extract of the fungus MSX 44407 showed potent cytotoxicity (96% and 
71% inhibition when tested against H460 cells at 20 and 2 μg/mL, respectively). The TIC of the 
crude extract revealed the presence of three major compounds eluting at 6.74, 7.01, and 7.25 min 
(Figure 4). ACD/Intellixtract analysis of the UPLC-HRMS data matched the second and third 
compounds to the cyclodepsipepetides enniatin D (9) and the unresolved isomers enniatins E1 
(10a) and E2 (10b), respectively; HRMS and MS/MS data confirmed these assignments 
(Figure 4). While the mass spectrometric data of the first eluting compound did not match any 
substance in the database, the HRMS data yielded a molecular formula of 
C33H57N3O9 (m/z 640.4138 [M + H]+, calcd for 640.4168). Searching the Dictionary of Natural 
Products(6) using the molecular formula resulted in one lead, enniatin B (8). Although 8 was not 
in the database, given its structurally similarity to compounds 9, 10a, and 10b, the extract was 
assigned as not of further interest. Twenty-nine enniatins, which are cyclohexadepsipeptides, 
have been characterized in the literature, either as single compounds or mixtures of unresolved 
isomers, and a recent review discusses their range of biological activities.(58) 
 
 
Figure 3. ACD/Intellixtract analysis of the TIC of an extract of MSX 39480. 
 
 
Figure 4. (+)-ESI SIC of the crude extract of MSX 44407 (m/z: 668, 654, 640). 
 
Dereplication of Aflatoxins 
 
Another culture, MSX 40080, showed potent cytotoxic activity when tested against H460 cells 
(95% and 76% growth inhibition when evaluated at 20 and 2 μg/mL, respectively). The TIC and 
PDA data of the crude extract suggested a series of structurally related compounds with 
distinctive UV absorption patterns. ACD/Intellixtract analysis of the UPLC-HRMS data led to 
the identification of five compounds, 5-methoxysterigmatocystin (11), brevianamide P (12), 
sterigmatocystin (13), aversin (14), and 6,8-di-O-methyl averufin (15). These assignments were 
confirmed by checking the HRMS and MS/MS spectra and UV absorption maxima with those in 
the database (Figures 5 and 6). Aflatoxins are regarded as nuisance mycotoxins with potent 
biological activity; hence their facile and rapid dereplication is important. These toxins have 
been investigated extensively due to their carcinogenic effects,(59) particularly in contaminated 
grains.(60) 
 
 
Figure 5. (A) (+)-ESI TIC, (B) SIC (m/z: 325, 355, 369, 378, and 397 for peaks 13, 11, 14, 12, 
and 15, respectively), and (C) UPLC-PDA of the crude extract of MSX 40080. 
 
 
Figure 6. (+)-HRESIMS and PDA spectra of compounds 11–15. 
 
In conclusion, UPLC-PDA-HRMS-MS/MS methodology has been developed and implemented 
for the dereplication of cytotoxic secondary metabolites in crude extracts of fungal cultures. This 
methodology has several attributes that distinguish it from previous systems. First, the database, 
which includes full-scan high-resolution mass spectra and MS/MS spectra from both the 
positive- and negative-ionization modes coupled with UV-absorption maxima and retention 
times, is the first to be constructed based on cytotoxic fungal secondary metabolites. 
Furthermore, the use of UPLC enables a rapid (10 min) chromatographic method, the fastest 
utilized in a comprehensive natural product dereplication strategy. This in turn facilitates the 
rapid nature of the protocol, such that less than 25 min, including the time for sample 
preparation, is needed to acquire and interpret the data. Moreover, the use of HRMS and MS/MS 
data imparts a high degree of confidence in the structure of the dereplicated leads. Coupling 
these data with the use of ACD/IntelliXtract, which extracts all chromatographic components in 
the LC-MS data sets and automatically assigns each as [M + H]+ or [M – H]−, expedites the 
identification process. In particular, the capability of ACD/IntelliXtract to deconvolute 
overlapping and coeluting components makes it possible to dereplicate trace compounds and 
enables the application of a short (10 min) chromatographic run time. Finally, the method was 
designed as a qualitative tool, and as such, the sensitivity for individual compounds was not 
measured a priori, especially since sensitivity is compound specific. However, the coupling of 
the resolving power of the UPLC with the enhanced sensitivity of mass spectrometry enabled the 
detection of trace amounts of compounds in crude extracts. In using this protocol for over two 
years on hundreds of samples, compounds present in as low as 0.22 mg/g of extract were 
detected readily. 
 
A promising side application of the dereplication methodology developed could be the detection 
and identification of mycotoxins in food commodities and agricultural products. Mycotoxins 
have attracted worldwide attention due to their profound negative economic consequences. It has 
been estimated that one-quarter of the world’s crops are contaminated with mycotoxins. Losses 
in the United States and Canada due to mycotoxins on the feed and livestock industries are on 
the order of $5 billion annually.(61, 62) The protocol described could be utilized in any 
laboratory having a mass spectrometer coupled with a UPLC, using the same analytical column, 
thereby enabling the identification of a suite of mycotoxins, even without reference standards. 
 
Experimental Section 
 
General Experimental Procedures 
 
HRESIMS was performed on a Thermo LTQ Orbitrap XL mass spectrometer (ThermoFisher, 
San Jose, CA, USA) equipped with an electrospray ionization source. Source conditions in the 
positive-ionization mode were set at 275 °C for the capillary temperature, 4.5 kV for the source 
voltage, 20 V for capillary voltage, and 95 V for the tube lens. For the negative-ionization mode, 
the source conditions for temperature were 3.5 kV for the source voltage, 42 V for capillary 
voltage, and 110 V for the tube lens. Nitrogen was utilized for the sheath gas and set to 25 and 20 
arb for the positive and negative modes, respectively. For the negative-ionization mode, nitrogen 
was also used as an auxiliary gas and set at 10 arb. In both modes, two scan events were carried 
out, full-scan (100–2000) and ion-trap MS/MS of the most intense ion from the parent mass list 
utilizing CID with a normalized collision energy of 30. External instrument calibration was 
performed using an LTQ ESI positive-ion calibration solution consisting of caffeine (20 μg/mL), 
MRFA (1 μg/mL), and Ultramark 1621 (0.001%) in an aqueous solution of CH3CN (50%), 
MeOH (25%), and acetic acid (1%). For the ESI negative-ion calibration, sodium dodecyl sulfate 
(2.9 μg/mL) and sodium taurocholate (5.4 μg/mL) were added to the LTQ ESI calibration 
solution instead of caffeine and MRFA. Thermo Scientific Xcalibur 2.1 software was used for 
instrument control and data analysis. UPLC was carried out on a Waters Acquity system [using a 
BEH C18 (2.1 × 50 mm, 1.7 μm) column (Waters Corp., Milford, MA, USA) equilibrated at 40 
°C]. A mobile phase consisting of CH3CN–H2O (acidified with 0.1% formic acid) was used, 
starting with 15:85 then increasing linearly to 100% CH3CN within 8 min, holding for 1.5 min, 
and then returning to the starting conditions within 0.5 min. An Acquity UPLC photodiode array 
detector was used to acquire PDA spectra, which were collected from 200 to 500 nm with 4 nm 
resolution. 
 
Reference Standards 
 
Secondary metabolites were isolated and characterized from the Mycosynthetix Inc. library of 
filamentous fungi, as described previously.(19, 30, 32-34, 58, 63-66) 
 
Extraction Procedure 
 
Small-scale cultures of fungi were grown on a solid, grain-based medium in 250 mL Erlermeyer 
flasks, as described in detail previously.(30, 33, 34) To each flask was added 60 mL of 1:1 
MeOH–CHCl3. The culture was chopped with a spatula and shaken overnight (∼16 h; at ∼100 
rpm) at rt. Each sample was filtered using vacuum, and the remaining residues were washed with 
small volumes of 1:1 MeOH–CHCl3. To the filtrate were added 90 mL of CHCl3 and 150 mL of 
H2O; the mixture was stirred for 2 h and then transferred into a separatory funnel. The bottom 
layer was drawn off into a round-bottomed flask and evaporated to dryness. The dried organic 
extract was reconstituted in 100 mL of 1:1 MeOH–CH3CN and 100 mL of hexanes. The biphasic 
solution was stirred for 1 h and then transferred to a separatory funnel. The MeOH–CH3CN layer 
was drawn off and evaporated to dryness under vacuum. This defatted material was then 
submitted for cytotoxic activity evaluation using a set of three cancer cell lines, as described 
previously.(35, 36) Extracts displaying potent cytotoxic activities (i.e., less than 20% survival 
when tested at 20 μg/mL) were dereplicated. A submilligram aliquot of the bioactive extracts 
was used for dereplication analysis by dissolving the extract in equal volumes of MeOH and 
dioxane to obtain a final concentration of 2 mg/mL in a total volume of 150 μL. 
 
Data Analysis 
 
Data from 172 fungal secondary metabolites are in the Supporting Information (Table S1), which 
lists the metabolites, molecular formula, retention time, UV-absorption maxima, high-resolution 
full-scan mass spectra, and MS-MS data (top 10 most intense peaks), utilizing both the positive- 
and negative-ionization modes. ACD MS Manager with add-in software IntelliXtract, Advanced 
Chemistry Development, Inc. (Toronto, Canada), was used for the primary analysis of the LC-
MS data. 
 
Cytotoxicity Assay 
 
The cytotoxicity measurements against the MCF-7(67) human breast carcinoma (Barbara A. 
Karmanos Cancer Center), NCI-H460(68) human large cell lung carcinoma (HTB-177, 
American Type Culture Collection (ATCC), and SF-268(69) human astrocytoma (NCI 
Developmental Therapeutics Program) cell lines were performed as described previously.(35, 
36) 
 
Supporting Information 
 
(+)-ESI TIC and SIC of a mixture of 10 standard compounds and their structures. A database of 
172 fungal secondary metabolites including molecular formula, retention time, UV-absorption 
maxima, HRMS, and MS/MS (top 10 intense peaks), utilizing both positive and negative 
ionization modes. This information is available free of charge via the Internet 
at http://pubs.acs.org. 
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